(NASDAQ: KZR) Kezar Life Sciences's forecast annual revenue growth rate of 37.47% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.56%.
Kezar Life Sciences's revenue in 2023 is $7,000,000.On average, 2 Wall Street analysts forecast KZR's revenue for 2023 to be $290,771,852, with the lowest KZR revenue forecast at $72,692,963, and the highest KZR revenue forecast at $508,850,741. On average, 1 Wall Street analysts forecast KZR's revenue for 2024 to be $1,599,245,186, with the lowest KZR revenue forecast at $1,599,245,186, and the highest KZR revenue forecast at $1,599,245,186.
In 2027, KZR is forecast to generate $673,863,767 in revenue, with the lowest revenue forecast at $673,863,767 and the highest revenue forecast at $673,863,767.